ID
IDXX.US IDEXX Laboratories Inc
- Market cap
- USD 55.5B
- P/E
- 47.5x
- P/B
- 29.68x
- ROE
- 66.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IDXX.US undervalued?
Graham numberThe Graham number of IDEXX Laboratories Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
IDEXX Laboratories Inc fundamental analysis
No fundamental analysis for IDEXX Laboratories Inc yet.
IDEXX Laboratories Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About IDEXX Laboratories Inc
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagu…
Full company profileIDEXX Laboratories Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
IDEXX Laboratories Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.78B | 1.97B | 2.21B | 2.41B | 2.71B | 3.22B | 3.37B | 3.66B | 3.90B | 4.30B | 4.76B |
| Gross Profit | 975M | 1.10B | 1.24B | 1.37B | 1.57B | 1.89B | 2.00B | 2.19B | 2.38B | 2.66B | 3.02B |
| Operating Income | 350M | 413M | 491M | 553M | 695M | 932M | 899M | 1.10B | 1.13B | 1.36B | 1.59B |
| EBITDA | 428M | 496M | 575M | 641M | 791M | 1.04B | 1.01B | 1.10B | 1.28B | 1.51B | 1.76B |
| Net Income | 222M | 263M | 377M | 428M | 582M | 745M | 679M | 845M | 888M | 1.06B | 1.25B |
| EPS | 2.44 | 2.94 | 4.26 | 4.89 | 6.71 | 8.60 | 8.03 | 10 | 11 | 13 | 16 |
| Balance Sheet | |||||||||||
| Total Assets | 1.53B | 1.71B | 1.54B | 1.83B | 2.29B | 2.44B | 2.75B | 3.26B | 3.29B | 3.35B | 3.71B |
| Total Liabilities | 1.64B | 1.77B | 1.55B | 1.65B | 1.66B | 1.75B | 2.14B | 1.78B | 1.70B | 1.75B | 1.84B |
| Shareholders' Equity | -108M | -54.1M | -9.51M | 177M | 632M | 690M | 609M | 1.48B | 1.60B | 1.61B | 1.87B |
| Cash & Short-term Investments | 392M | 472M | 124M | 90.3M | 384M | 144M | 113M | 454M | 288M | 180M | 198M |
| Total Debt | 1.20B | 1.26B | 1.00B | 1.07B | 1.00B | 1.03B | 1.47B | 1.07B | 266M | 1.08B | 973M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 335M | 373M | 400M | 459M | 648M | 756M | 543M | 907M | 929M | 1.18B | 1.42B |
| Capital Expenditure | 64.8M | 76.7M | 123M | 155M | 108M | 120M | 149M | 134M | 131M | 125M | 114M |
| Free Cash Flow | 270M | 297M | 277M | 304M | 540M | 636M | 394M | 773M | 798M | 1.05B | 1.30B |
| Ratios | |||||||||||
| ROE | - | - | - | 241.0% | 92.0% | 107.9% | 111.6% | 56.9% | 55.7% | 66.0% | 66.6% |
| ROA | 14.5% | 15.4% | 24.5% | 23.3% | 25.4% | 30.6% | 24.7% | 25.9% | 27.0% | 31.6% | 33.6% |
| Net Profit Margin | 12.5% | 13.4% | 17.0% | 17.8% | 21.5% | 23.2% | 20.2% | 23.1% | 22.8% | 24.6% | 26.2% |
| Debt to Equity | - | - | - | 6.03x | 1.59x | 1.49x | 2.41x | 0.72x | 0.17x | 0.67x | 0.52x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
IDEXX Laboratories Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 46.6M | 0.54 | 6.3% |
| 2020 | USD 51.3M | 0.59 | 8.8% |
| 2019 | USD 36.1M | 0.41 | 8.4% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jun 16, 2015.
Who owns IDEXX Laboratories Inc
- Insiders 0.68%
- Institutions 94.64%
- Public & others 4.68%
- Shares outstanding 78.8M
- Free float 78.5M
Top funds holding IDXX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.50M | 3.17% | -0.27% | Sep 2026 |
| Vanguard 500 Index Investor | 2.07M | 2.63% | -1.22% | Sep 2026 |
| Vanguard MStar Mid Cap Index Instl | 1.69M | 2.14% | -1.13% | Sep 2026 |
| Invesco QQQ Trust | 1.64M | 2.08% | -0.10% | Oct 2026 |
| iShares Core S&P 500 ETF | 1.05M | 1.33% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 1.02M | 1.30% | -0.01% | Sep 2026 |
| Vanguard MStar Growth Index Investor | 1.00M | 1.27% | +7.28% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 964K | 1.22% | -0.25% | Oct 2026 |
| Baron Partners Retail | 798K | 1.01% | -5.70% | Sep 2026 |
| American Funds AMCAP A | 733K | 0.93% | 0.00% | Sep 2026 |
| Vanguard MStar Mid Cap Growth ETF | 618K | 0.79% | +2.06% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 576K | 0.73% | +0.88% | Oct 2026 |
| T. Rowe Price Mid-Cap Growth | 532K | 0.68% | 0.00% | Sep 2026 |
| Vanguard Institutional Index I | 417K | 0.53% | -1.25% | Sep 2026 |
| Fidelity Contrafund | 394K | 0.50% | +12.31% | Sep 2026 |
| Invesco S&P 500® Equal Weight ETF | 383K | 0.49% | +0.16% | Oct 2026 |
| Invesco NASDAQ 100 ETF | 374K | 0.48% | +0.15% | Oct 2026 |
| iShares Russell Mid-Cap Growth ETF | 374K | 0.47% | -0.07% | Oct 2026 |
| iShares Russell Mid-Cap ETF | 336K | 0.43% | -0.06% | Oct 2026 |
| Fidelity Mid Cap Index | 309K | 0.39% | +2.61% | Sep 2026 |
Top institutions holding IDXX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 8.17M | 10.37% | -2.34% | Jun 2026 |
| Vanguard Capital Management, LLC | 5.15M | 6.54% | -0.58% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.90M | 4.95% | -0.37% | Jun 2026 |
| State Street Corp | 3.75M | 4.76% | +2.03% | Jun 2026 |
| Amvescap Plc. | 3.61M | 4.58% | +7.81% | Jun 2026 |
| Geode Capital Management, LLC | 2.56M | 3.25% | -3.69% | Jun 2026 |
| BAMCO Inc | 1.98M | 2.51% | +21.02% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.36M | 1.72% | +3.05% | Jun 2026 |
| Bank of New York Mellon Corp | 1.19M | 1.51% | -20.68% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 1.07M | 1.35% | +27.21% | Jun 2026 |
| Fundsmith LLP | 1.02M | 1.29% | -30.42% | Jun 2026 |
| Blair William & Co | 919K | 1.17% | -2.94% | Jun 2026 |
| Northern Trust Corp | 918K | 1.17% | +0.68% | Jun 2026 |
| UBS Asset Mgmt Americas Inc | 911K | 1.16% | +4.55% | Jun 2026 |
| FMR Inc | 823K | 1.04% | +190.71% | Jun 2026 |
| Capital Research Global Investors | 791K | 1.00% | +0.28% | Sep 2026 |
| JPMorgan Chase & Co | 756K | 0.96% | -3.09% | Jun 2026 |
| American Century Companies Inc | 749K | 0.95% | -7.29% | Sep 2026 |
| The Goldman Sachs Group Inc | 739K | 0.94% | +3.04% | Jun 2026 |
| Wellington Management Company LLP | 727K | 0.92% | -1.19% | Jun 2026 |
IDEXX Laboratories Inc company profile
- Company name
- IDEXX Laboratories Inc
- Ticker
- IDXX.US
- Exchange
- USA Stocks
- Listed since
- Jun 21, 1991
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 11,000
- Fiscal year end
- December
- Address
- One IDEXX Drive, Westbrook, ME, United States, 04092
- Phone
- 207 556 0300
- Website
- idexx.com
About IDEXX Laboratories Inc
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
IDEXX Laboratories Inc management
10- Mr. Jonathan J. MazelskyExecutive Chairman · born 1961
- Mr. Andrew EmersonExecutive VP, CFO & Treasurer · born 1983
- Mr. Michael J. LaneExecutive VP and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology · born 1968
- Dr. Martin Smith Ph.D.Executive Vice President of Global Operations and R&D · born 1968
- Mr. Michael G. Erickson Ph.D.CEO, President & Director · born 1974
- Mr. Bob AsmannSenior Vice President of Global Operations
- Mr. Amit GuptaSenior VP, Chief Digital & Information Officer
- Ms. Sharon E. Underberg J.D.Executive VP, General Counsel, & Corporate Secretary · born 1961
- Ms. Julie GodonSenior VP & Global Marketing Officer
- Mr. Michael P. JohnsonExecutive VP & Chief Human Resources Officer · born 1978